1431932-97-6

Basic information

• Product Name: (2S)-isopropyl 2-((((3aR,4R,6R,6aR)-6-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-6-cyano-6a-methyl-2-oxotetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)(phenoxy)phosphorylamino)propanoate
• CAS NO: 1431932-97-6
• Molecular Weight: 600.525
• Mol File: 1431932-97-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S)-isopropyl 2-((((3aR,4R,6R,6aR)-6-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-6-cyano-6a-methyl-2-oxotetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)(phenoxy)phosphorylamino)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-isopropyl 2-((((3aR,4R,6R,6aR)-6-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-6-cyano-6a-methyl-2-oxotetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)(phenoxy)phosphorylamino)propanoate(1431932-97-6)
• EPA Substance Registry System: (2S)-isopropyl 2-((((3aR,4R,6R,6aR)-6-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-6-cyano-6a-methyl-2-oxotetrahydrofuro[3,4-d][1,3]dioxol-4-yl)methoxy)(phenoxy)phosphorylamino)propanoate(1431932-97-6)

Safety Data

• Hazardous Substances Data: 1431932-97-6(Hazardous Substances Data)

Upstream product

• 1350735-57-7 (2S)-isopropyl 2-((((2R,3R,4R,5R)-5-(4-aminopyrrolo[1,2-f]-[1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphorylamino)propanoate 
• 530-62-1 1,1'-carbonyldiimidazole 
• 937046-98-5 7-bromo-pyrrolo[2,1-f][1,2,4]triazin-4-ylamine 
• 917567-08-9 (3R,4R,5R)-3,4-bis(benzyloxy)-5-[(benzyloxy)methyl]-3-methyloxolan-2-one 
• 1272971-35-3 2′,3′,5′-O-tribenzyl-1′-cyano-2′-C-methyl-4-aza-7,9-dideazaadenosine 
• 1191237-49-6 1′-cyano-2′-C-methyl-4-aza-7,9-dideazaadenosine 
• 770-12-7 O-phenyl phosphorodichloridate 
• 261909-49-3 phenyl(isopropoxy-L-alaninyl) phosphorochloridate 
• 39613-92-8 alanine isopropyl ester hydrochloride 

Relevant articles and documents

Discovery of the first C -nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients

Hepatitis C virus (HCV) infection presents an unmet medical need requiring more effective treatment options. Nucleoside inhibitors (NI) of HCV polymerase (NS5B) have demonstrated pan-genotypic activity and durable antiviral response in the clinic, and they are likely to become a key component of future treatment regimens. NI candidates that have entered clinical development thus far have all been N-nucleoside derivatives. Herein, we report the discovery of a C-nucleoside class of NS5B inhibitors. Exploration of adenosine analogs in this class identified 1′-cyano-2′-C-methyl 4-aza-7,9-dideaza adenosine as a potent and selective inhibitor of NS5B. A monophosphate prodrug approach afforded a series of compounds showing submicromolar activity in HCV replicon assays. Further pharmacokinetic optimization for sufficient oral absorption and liver triphosphate loading led to identification of a clinical development candidate GS-6620. In a phase I clinical study, the potential for potent activity was demonstrated but with high intra- and interpatient pharmacokinetic and pharmacodynamic variability.